Novo Nordisk's CagriSema trial raised concerns as patients reported weight loss but significant side effects. Investors ...

Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.

Welcome to the full-year 2024 Novo Nordisk earnings conference call. [Operator instructions] Please be advised that today's ...

Novo Nordisk A/S, No. 25-cv-00713 ... claim the company misrepresented the likelihood of CagriSema achieving at least 25% weight loss in the study. The suit alleges that Novo Nordisk created ...

The trial showed that patients treated with CagriSema exhibited weight loss of 22.7% after 68 weeks ... your rights to seek a recovery. There is no cost or obligation to participate.

At the high dose, the average placebo-adjusted weight loss from the weekly administered drug was 11.3%. No plateau of effect was observed, which suggests the potential for greater weight loss with ...

In October 2024, when talking about the company, Cramer quipped: “No… The guys who told ... reaction to Novo’s more enhanced CagriSema weight loss treatment was negative, we believe this ...

Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.

Novo Nordisk (NVO) stock in focus as company announces new Phase 3 trial for its next-gen weight loss drug CagriSema despite ...

Novo Nordisk defended its obesity drug CagriSema despite disappointing trial data. The company remains optimistic about its efficacy compared to Wegovy. Upcoming trials aim to harness its weight-loss ...

CagriSema could still be a commercial success, though, and amycretin's recent results highlight the fact that Novo Nordisk's weight loss pipeline is deep.